6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s232. https://doi.org/10.25251/skin.7.supp.232